Cazitel 230/20 Mg Flavoured Film-Coated Tablets For Cats
Issued: April 2014
Summary of Product Characteristics
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Cazitel 230/20 mg Flavoured Film-Coated Tablets for Cats
Cazitel 230/20 mg Film-Coated Tablets for Cats (Finland, Sweden)
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains Pyrantel embonate 230 mg and Praziquantel 20 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
A white to off white round, biconvex coated tablet with a breakline on one side and plain on the other side.
The tablet can be divided into equal halves.
4. CLINICAL PARTICULARS
4.1 Target species
4.2 Indications for use, specifying the target species
For the treatment of mixed infections caused by the following gastrointestinal roundworms and tapeworms:
Roundworms:Toxocara cati, Toxascaris leonina,
Tapeworms:Dipylidium caninum, Taeniataeniaeformis, Echinococcus multilocularis.
Do not use simultaneously with piperazine compounds.
Do not use in kittens less than 6 weeks of age.
Do not use in animals with known hypersensitivity to the active substances or to any of the excipients.
4.4 Special warnings for each target species
Fleas serve as intermediate hosts for one common type of tapeworm – Dipylidium caninum. Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc. is undertaken.
Parasitic resistance to a certain class of anthelmintics can occur after frequent and repeated use of an anthelmintic from this class.
4.5 Special precautions for use
Special precautions for use in animals
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In the interests of good hygiene, persons administering the tablets directly to the cat, or by adding them to the cat’s food, should wash their hands afterwards.
In case of accidental ingestion, seek medical advice and show the package leaflet to the physician.
4.6 Adverse reactions (frequency and seriousness)
4.7 Use during pregnancy, lactation or lay
Do not use during pregnancy but may be used during lactation.
4.8 Interaction with other medicinal products and other forms of interaction
Do not use simultaneously with piperazine compounds.
4.9 Amounts to be administered and administration route
To ensure administration of a correct dose, body weight should be determined as accurately as possible.
The recommended dose is: 20 mg/kg pyrantel (57.5mg/kg pyrantel embonate)and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 4 kg bodyweight.
1.0 - 2.0 kg
2.1 - 4.0 kg
4.1 - 6.0 kg
6.1 - 8.0 kg
Administration and duration of treatment
Single oral administration. The tablet should be given directly to the cat, but if necessary can be disguised in food.
In ascarid infestation, especially in kittens, complete elimination cannot be expected, so a risk of infection for humans can persist. Repeat treatments should, therefore, be carried out with a suitable roundworm product at 14 day intervals until 2-3 weeks after weaning.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
After doses higher than 5 times the recommended dose, signs of intolerance such as vomiting have been observed.
4.11 Withdrawal period(s)
5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Anthelmintics, praziquantel combinations.
ATC vet code: QP52AA51
5.1 Pharmacodynamic properties
This product contains anthelmintics active against gastrointestinal roundworms and tapeworms. The product contains two active substances, as follows:
Pyrantel embonate (pamoate), a tetrahydropyrimidine derivative
Praziquantel, a partially hydrogenated pyrazinoisoquinoline derivative.
Pyrantel acts as a cholinergic agonist. Its mode of action is to stimulate nicotinic cholinergic receptors of the parasite, induce spastic paralysis and thereby allow expulsion from the gastro-intestinal (GI) system by peristalsis.
Praziquantel is very rapidly absorbed and distributed throughout the parasite. Both in vitro and in vivo studies have shown that praziquantel causes severe damage to the parasite integument, resulting in contraction and paralysis. There is an almost instantaneous tetanic contraction of the parasite musculature and a rapid vacuolization of the syncytial tegument. This rapid contraction has been explained by changes in divalent cation fluxes, especially calcium.
In this fixed combination, pyrantel is active against the following ascarids: Toxocara cati, and Toxascaris leonina. Praziquantel is effective against tapeworms in particular Dipylidium caninumand Taenia taeniaeformis.
Since it contains praziquantel, the product is effective against Echinococcus multilocularis.
5.2 Pharmacokinetic particulars
Praziquantel is rapidly absorbed, metabolised and distributed in the body. It is also believed to be excreted back into the intestinal lumen by the mucous membrane.
Following administration of the product to cats, peak plasma concentrations of praziquantel were achieved by approximately 2 hours.
Pyrantel is poorly absorbed so it is expected that a large proportion of the administered dose remains in the GIT where it exerts its therapeutic effect and it is excreted largely unchanged in the faeces.
Following administration of the product to cats, peak plasma concentrations of pyrantel were achieved by approximately 3 hours.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Colloidal anhydrous silica,
Grilled meat flavour
Opadry II White consisting of Polyvinyl Alcohol, Titanium Dioxide (E171), Macrogol 3350 and Talc (E553b).
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale:4 years
Discard unused half tablets.
6.4. Special precautions for storage
This veterinary medicinal product does not require any special storage conditions
Nature and composition of immediate packaging
The product is presented in either:
Individual blisters made up of a PVC/PE/PCTFE white opaque copolymer and a 20µm heatseal lacquer/aluminium containing 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20 tablets.
Individual blisters made up of 45µm PVC/aluminium/orientated polyamide and a 20µm heatseal lacquer/aluminium containing 2 or 8 tablets.
The blisters are packed into cartons containing either: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 30, 32, 36, 40, 42, 44, 48, 50, 52, 56, 60, 64, 68, 70, 72, 76, 80, 84, 88, 92, 96, 98, 100, 104, 106, 108, 112, 116, 120, 128, 136, 140, 144, 150, 152, 160, 168, 176, 180, 184, 192, 200, 204, 206, 208, 216, 224, 232, 240, 248, 250, 280, 300, 500 or 1000 tablets
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements
7. MARKETING AUTHORISATION HOLDER
Chanelle Pharmaceuticals Manufacturing Ltd
8. MARKETING AUTHORISATION NUMBER
9. DATE OF FIRST AUTHORISATION
04 April 2014
10. DATE OF REVISION OF THE TEXT
Page 5 of 5